UK NHS cancer patients denied drugs due to inflated prices

Google+ Pinterest LinkedIn Tumblr +

drugs_tablets_oncology news australiaBy Sarah Boseley – The Guardian.

Research reveals how drug firms are charging health service such high prices, some treatments can no longer be offered

Cancer patients are being denied drugs on the NHS that could lengthen their lives because of unnecessarily exorbitant prices, say experts.

The drugs are cheap to make, and are available to patients in some other countries at much lower prices, according to new research.

Patients in the UK have been told the NHS will not pay for two such drugs because they are not cost-effective and they have been dropped from the list reimbursed by the government’s special cancer drugs fund.

The price of lapatinib (brand name Tyverb), for breast cancer, was set at $36,000 (£24,000) per patient per year in the UK but costs $17,724 in Thailand. Dasatinib (Sprycel), for leukaemia, was priced at $33,739 in the UK but at $15,423 in Brazil.

The researchers also ask why the UK is not succeeding in obtaining better discounts from drugs the NHS does use. Even some other high-income countries manage to barter the manufacturers down to lower prices than in the UK…read more.

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.